Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for INC280

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug INC280?

INC280 is an investigational drug.

There have been 31 clinical trials for INC280. The most recent clinical trial was a Phase 2 trial, which was initiated on May 31st 2017.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Array BioPharma, and Novartis.

There are seventeen US patents protecting this investigational drug and two hundred and seventy-four international patents.

Recent Clinical Trials for INC280
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%Novartis PharmaceuticalsPhase 2
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung CancerNovartis PharmaceuticalsPhase 2
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).Novartis PharmaceuticalsPhase 1

See all INC280 clinical trials

Clinical Trial Summary for INC280

Top disease conditions for INC280
Top clinical trial sponsors for INC280

See all INC280 clinical trials

US Patents for INC280

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
INC280   Start Trial Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA)   Start Trial
INC280   Start Trial Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide Novartis AG (Basel, CH)   Start Trial
INC280   Start Trial Combination therapy NOVARTIS AG (Basel, CH)   Start Trial
INC280   Start Trial Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,- 4]triazin-2-yl]benzamide and processes related to preparing the same INCYTE INCORPORATION (Wilmington, DE) INCYTE HOLDINGS CORPORATION (Wilmington, DE)   Start Trial
INC280   Start Trial Imidazotriazines and imidazopyrimidines as kinase inhibitors Incyte Corporation (Wilmington, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for INC280

Drugname Country Document Number Estimated Expiration Related US Patent
INC280 European Patent Office 3131552 2034-04-16   Start Trial
INC280 Japan 2017514806 2034-04-16   Start Trial
INC280 Japan 2019070012 2034-04-16   Start Trial
INC280 New Zealand 629860 2034-04-16   Start Trial
INC280 World Intellectual Property Organization (WIPO) 2015160868 2034-04-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.